INVA vs. OPK, MNKD, LGND, KNSA, IRWD, PHAT, TBPH, LXRX, DVAX, and XOMA
Should you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include OPKO Health (OPK), MannKind (MNKD), Ligand Pharmaceuticals (LGND), Kiniksa Pharmaceuticals (KNSA), Ironwood Pharmaceuticals (IRWD), Phathom Pharmaceuticals (PHAT), Theravance Biopharma (TBPH), Lexicon Pharmaceuticals (LXRX), Dynavax Technologies (DVAX), and XOMA (XOMA). These companies are all part of the "pharmaceutical preparations" industry.
OPKO Health (NASDAQ:OPK) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.
Innoviva has a net margin of 57.89% compared to Innoviva's net margin of -21.76%. OPKO Health's return on equity of 30.37% beat Innoviva's return on equity.
64.6% of OPKO Health shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 47.3% of OPKO Health shares are held by insiders. Comparatively, 1.4% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Innoviva had 1 more articles in the media than OPKO Health. MarketBeat recorded 5 mentions for Innoviva and 4 mentions for OPKO Health. OPKO Health's average media sentiment score of 1.03 beat Innoviva's score of 0.88 indicating that Innoviva is being referred to more favorably in the news media.
Innoviva has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
OPKO Health received 202 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 65.83% of users gave OPKO Health an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
OPKO Health presently has a consensus price target of $3.73, suggesting a potential upside of 195.63%. Given Innoviva's higher probable upside, equities research analysts plainly believe OPKO Health is more favorable than Innoviva.
OPKO Health has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
Summary
Innoviva beats OPKO Health on 10 of the 17 factors compared between the two stocks.
Get Innoviva News Delivered to You Automatically
Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innoviva Competitors List
Related Companies and Tools
